177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
- 6 May 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (10), 1869-1875
- https://doi.org/10.1007/s00259-010-1483-4
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study GroupJournal of Clinical Oncology, 2009
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and SurvivalJournal of Clinical Oncology, 2008
- The Nonuniformity of Antibody Distribution in the Kidney and its Influence on DosimetryRadiation Research, 2003
- Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.2002
- Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experienceSeminars in Nuclear Medicine, 2002
- Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignanciesSeminars in Nuclear Medicine, 2002
- [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlookAnnals Of Oncology, 1999
- Chemotherapy and biotherapy in neuroendocrine tumors.1993